FDA Approves Tirzepatide to Reduce Cardiovascular Risk in Adults with Type 2 Diabetes
Cardiovascular disease remains a major cause of morbidity and mortality among people with type 2 diabetes. Epidemiological studies estimate that as many as one in three U.S. adults with type 2 diabetes have undetected subclinical cardiovascular disease (1).
David A. D’Alessio, Director of Endocrinology and Metabolism at Duke University School of Medicine, emphasized that “heart health deserves attention throughout the course of treatment, not just after a serious cardiovascular event,” noting that while diabetes care often focuses heavily on glucose control, addressing cardiovascular risk remains an important component of comprehensive diabetes management (1).
On August 28, 2026, the U.S. Food and Drug Administration (FDA) approved tirzepatide (Mounjaro) to reduce the risk of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke, in adults with type 2 diabetes mellitus (T2DM) who are at high risk for these events (1,2).
Mechanism of Action of tirzepatide
Tirzepatide is a single-peptide molecule that acts as a dual GIP and GLP-1 receptor agonist (1,2). Its C20 fatty diacid moiety enables high albumin binding (99%), resulting in an elimination half-life of approximately 5 days and supporting once-weekly subcutaneous dosing (2). Tirzepatide enhances insulin secretion and reduces glucagon release in a glucose-dependent manner, while also improving insulin sensitivity and slowing gastric emptying (2).
Head-to-Head Evidence: The SURPASS-CVOT Trial
Over a median follow-up of 210.1 weeks (approximately 4 years), tirzepatide demonstrated non-inferiority to dulaglutide for MACE-3, with an 8% lower rate of composite events (HR: 0.92; 95.3% CI: 0.83, 1.01); superiority was not established (1,4). A primary endpoint event (composite of death from cardiovascular causes, myocardial infarction, or stroke) was observed in 801 patients (12.2%) in the tirzepatide group and 862 patients (13.1%) in the dulaglutide group, yielding a hazard ratio of 0.92 (5).
Safety profile of tirzepatide
The safety profile observed in SURPASS-CVOT was consistent with the established safety profile of tirzepatide (1,2). The most common adverse events were mild-to-moderate gastrointestinal symptoms, including nausea, diarrhoea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain, which occurred primarily during dose escalation (1,2).
Key safety warnings and precautions include:
Thyroid C-Cell Tumours: Tirzepatide carries a boxed warning based on findings of dose-dependent C-cell tumours in rodents; the relevance of these findings to humans is unknown (2).It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) (2).
Acute Pancreatitis: Monitor patients for severe abdominal pain that may radiate to the back. Discontinue tirzepatide if pancreatitis is suspected (2).
Renal Impairment: Severe gastrointestinal adverse reactions can result in dehydration and may increase the risk of acute kidney injury. Monitor renal function in patients with renal impairment who experience adverse reactions that could lead to volume depletion, particularly during treatment initiation and dose escalation (2).
Hypoglycemia: Concomitant use with insulin secretagogues or insulin may increase the risk of hypoglycemia and may require dose reduction of these background therapies (2).
Other Concerns: Monitor patients with a history of diabetic retinopathy for progression. Pulmonary aspiration has been reported in patients receiving GLP-1 receptor agonists undergoing procedures involving general anesthesia or deep sedation, potentially related to delayed gastric emptying (2).
Dosage and Administration
Tirzepatide is initiated at 2.5 mg subcutaneously once weekly (2). The dose may be increased in 2.5 mg increments after at least 4 weeks, up to a maximum adult dose of 15 mg once weekly (2). Injection sites should be rotated among the abdomen, thigh, and upper arm; upper-arm injections should be administered by another person (2). Tirzepatide should not be mixed with insulin in the same injection (2).
Storage: Unopened products should be stored refrigerated at 2°C to 8°C (36°F to 46°F) and protected from light (2).
Conclusion
By addressing glycemic control, body weight, and MACE risk through once-weekly administration, tirzepatide provides an additional therapeutic option for adults with type 2 diabetes who are at high risk for cardiovascular events. The cardiovascular findings from SURPASS-CVOT further expand the clinical evidence supporting tirzepatide in this population (1,4).
About the Author
Dr. Manisha Dadlani is a Dental Surgeon and Medical Writer with 5+ years of clinical experience and formal training in medical writing. She combines clinical expertise with analytical thinking to develop evidence-based, insight-driven content that supports effective scientific communication across the healthcare and life sciences landscape.
References:
Eli Lilly and Company. FDA approves Lilly’s Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. Available at: https://lilly.mediaroom.com/2026-08-28-FDA-approves-Lillys-Mounjaro-tirzepatide-to-reduce-cardiovascular-risk-in-adults-with-type-2-diabetes Accessed on 20 September, 2026.
Eli Lilly and Company. Mounjaro (tirzepatide) injection, for subcutaneous use: Highlights of prescribing information. Initial U.S. approval: 2022. Available at:
https://uspl.lilly.com/mounjaro/mounjaro.html Accessed on 20 September, 2026.
Fang M, Wang D, Tang O, et al. Subclinical cardiovascular disease in US adults with and without diabetes. Journal of the American Heart Association. 2023 Jun 6;12(11): e029083.
ClinicalTrials.gov. A study of tirzepatide (LY3298176) compared with dulaglutide on major cardiovascular events in participants with type 2 diabetes (NCT04255433). Available at:
https://clinicaltrials.gov/study/NCT04255433 Accessed on 20 September, 2026.
Nicholls SJ, Pavo I, Bhatt DL, et al; SURPASS-CVOT Investigators. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025 Dec 18;393(24):2409-2420.
Disclaimer
The content published on this platform has been developed by independent medical writers from diverse healthcare backgrounds, including members of the MedWriters Alumni Network. While every effort has been made to ensure accuracy, the authors, Rxnews team, partners, agents, and sponsors accept no responsibility for errors, omissions, or inaccuracies in this article, whether due to negligence or otherwise, nor for any consequences arising from its use. Inclusion or exclusion of any product does not imply endorsement or rejection by the publisher. For complaints or feedback, please write to contact@rxnews.in
Comments